Doctors on the Take from Big Pharma By Mrs Vera West

This information relates to the US, but it is likely that something similar would be found in Australia if the matter was investigated. Researchers at Pennsylvania State University, found that approximately 57 percent of doctorsreceived a total of around $12.1 billion from medical device manufacturers and pharmaceutical drug makers, Big Pharma, between 2013 and 2022, which is nearly six in ten doctors. According to data obtained from the US platform Open Payments, which is a publicly accessible national database where drug and medical device companies disclose payments and gifts made to physicians, from August 2013 to August 2022, American drug and device manufacturers made more than 85 million individual payments to 826,313 doctors.

That is what is known; as in Australia, Big Pharma reps frequently visit doctors to inform them of the latest drugs, and bring gifts. My former doctor proudly told me once, that the bottle of expensive wine on his desk was a gift from the drug rep who had just left. He said that the rep also brought with him a lunch, which was so salty that he needed a drink of water. Or, maybe, a blood pressure tablet!

The clear and evident problems here are conflicts of interest and bias regarding the drugs that have been pushed. This does nothing to restore my faith in the medical profession.

https://www.naturalnews.com/2024-04-05-report-finds-doctors-received-billions-big-pharma.html

"A report has found that nearly six in 10 doctors in the United States received payments from Big Pharma firms between 2013 and 2022.

This is according to a study done by researchers at Pennsylvania State University, which found that around 57 percent of doctors collectively received approximately $12.1 billion from medical device manufacturers and pharmaceutical drug makers between 2013 and 2022.

"Despite evidence that financial conflicts of interest may influence physician prescribing and may damage patients' trust in medical professionals, such payments remain pervasive," the researchers wrote.

The researchers used data from the platform Open Payments – a publicly accessible national database where drug and medical device companies disclose payments and gifts made to physicians – for their study. They found that from August 2013 to August 2022, American drug and device manufacturers made more than 85 million individual payments to 826,313 of the more than 1.4 million eligible doctors in the United States.

The payments that the researchers included in their study were both in cash and non-cash equivalents. Most went to consulting services and non-consulting fees, such as payments for serving as a speaker. Physicians were also showered with food and beverages, travel and lodging, entertainment, education, grants, charitable contributions, honoraria and other kinds of non-cash gifts.

Thirty-nine medical specialties were analyzed in the study and the researchers found that orthopedic surgeons received the largest total sum of payments, at $1.36 billion. After orthopedic surgeons, the specialties that received the largest total sum of payments were neurologists and psychiatrists, who received $1.32 billion, and cardiologists, who received $1.29 billion.

Although the median payment to doctors was $48, payments to the top 0.1 percent of doctors were far higher and differed depending on specialty. The average amount paid to this top class of physician was $4,826,944 for orthopedic surgeons, $3,197,675 for cardiologists and $2,588,819 for neurologists and psychiatrists.

Other major earning specialties include hematology and oncology ($825 million), internal medicine ($588 million), endocrinology ($546 million), family medicine ($479 million), rheumatology, allergy and immunology ($464 million), dermatology ($462 million) and gastroenterology ($441 million). The lowest earners were pediatricians.

Twenty-five drugs and medical devices were associated with the largest payments. Roughly 94 percent of payments were associated with one or more of the 25 marketed medical products.

For drugs, the largest payments were for the blood thinners rivaroxaban – sold by Bayer under the brand name Xarelto – and apixaban – sold by Pfizer as Eliquis. Both are medicines used to prevent blood clots and stroke in people with atrial fibrillation.

They were followed by the psoriasis drug adalimumab, sold by AbbVie as Humira; and canaglifozin and empagliflozin, both used to treat Type 2 diabetes. The former is sold by Johnson & Johnson as Invokana and the latter by Eli Lilly as Jardiance.

The top medical device related to industry payment was the Da Vinci surgical system – a robotic surgical system. More than 60,000 surgeons globally are trained on the Da Vinci, and manufacturer Intuitive Surgical is on an aggressive campaign to get more surgeons to train to use it."